New Delhi: Kolkata-based medtech innovator Innovodigm has raised ₹5.5 crore in seed funding to accelerate the development of its game-changing Microneedle Array Patch (MAP) – a pain-free, needleless vaccine delivery platform.
The funding round was led by IAN Group, with ₹4.5 crore contributed by the angel network, and the remainder from PadUp Ventures.
Founded by Dr Jhimli Manna and Dr Ayan Chatterjee, Innovodigm is redefining vaccine delivery in India and beyond.
Its proprietary MAP platform enables painless, thermostable, and sharps-free vaccine administration, eliminating the need for refrigeration and reducing biohazard waste.
Also Read: Deeptech Startup AuraML Raises USD 1M Pre-Seed Round Led by Turbostart
The patch delivers thermostabilized vaccines that remain viable for up to 120 days at 40°C – an ideal solution for rural and resource-limited regions.
With this latest infusion of capital, Innovodigm plans to optimize its manufacturing processes, expand infrastructure, scale its team, and complete third-party preclinical validation in preparation for clinical trials scheduled for next year.
The company has already signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer.
“Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been instrumental in building our innovation on deep scientific roots,” said Dr Jhimli Manna, CEO of Innovodigm. “This seed funding enables us to take our MAP platform from lab to field and make a global impact by transforming vaccine delivery and accessibility.”
IAN Group’s Padmaja Ruparel noted, “Innovodigm’s platform has the potential to revolutionize global vaccine distribution, particularly in geographies where cold-chain and needle-based immunization are limiting factors. Their deep-tech foundation and strong regulatory roadmap make this a standout health-tech opportunity.”
Also Read: InnoVent Hackathon 2026 Opens for Entries, Focuses on AI and Smart Mobility Innovation
The MAP platform has garnered prestigious recognition, being named among the Top 2 Technologies at the Nano Electronics Showcase 2025 by the Ministry of Electronics & IT, and a featured innovation at the G20 Summit under India’s National Health Mission.
Innovodigm’s future roadmap includes adapting the patch for multiple vaccines – such as measles, hepatitis, influenza, and COVID-19 boosters – and establishing decentralized manufacturing hubs in underserved regions.
The technology is patent-protected, needle-free, waste-reducing, and easy to administer, requiring minimal training and enabling safer immunization campaigns.
About Innovodigm
Innovodigm Pvt. Ltd. is a deep-tech spin-off from IIT Kharagpur’s Microelectronics and MEMS Lab. The company’s flagship Microneedle Array Patch (MAP) offers a painless, thermostable, and sharps-free vaccine delivery solution to combat cold-chain challenges and needle-related health risks. The platform addresses critical immunization gaps globally and aims to enable scalable, last-mile vaccination solutions.
About IAN Group
IAN Group is India’s largest platform for early-stage investments, operating through the IAN Angel Network, IAN Fund I, and the IAN Alpha Fund. The group supports high-potential startups with capital, mentorship, and global market access, and has funded startups across 19 sectors in India and 7 other countries.
